Cargando…

Stakeholder-Driven Intervention Development for Dialysis Trials Using a Design Sprint Methodology

RATIONALE & OBJECTIVE: Stigma contributes to ineffective treatment for pain among individuals with kidney failure on dialysis, particularly with buprenorphine pain treatment. To address stigma, we adapted a Design Sprint, an industry-developed structured exercise where an interdisciplinary group...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalowski, Allison, Cavanaugh, Kerri L., Hamm, Megan, Wilkie, Caroline, Olejniczak, Donna M., Eneanya, Nwamaka D., Colditz, Jason, Jhamb, Manisha, Bulls, Hailey W., Liebschutz, Jane M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630159/
https://www.ncbi.nlm.nih.gov/pubmed/38028030
http://dx.doi.org/10.1016/j.xkme.2023.100729
Descripción
Sumario:RATIONALE & OBJECTIVE: Stigma contributes to ineffective treatment for pain among individuals with kidney failure on dialysis, particularly with buprenorphine pain treatment. To address stigma, we adapted a Design Sprint, an industry-developed structured exercise where an interdisciplinary group works over 5 days to clarify the problem, identify and choose a solution, and build and test a prototype. STUDY DESIGN: Adapted Design Sprint which clarified the problem to be solved, proposed solutions, and created a blueprint for the selected solution. SETTINGS & PARTICIPANTS: Five individuals with pain and kidney disease receiving dialysis, 5 physicians (nephrology, palliative care, and addiction medicine) and 4 large dialysis organization leaders recruited for specific expertise or experience. Conducted through online platform (Zoom) and virtual white board (Miro board). ANALYTICAL APPROACH: Descriptions of the Design Sprint adaptations and processes. RESULTS: To facilitate patient comfort, a patient-only phase included four 90-minute sessions over 2-weeks, during which patient participants used a mapping process to define the critical problem and sketch out solutions. In a physician-only phase, consisting of two 120-minute sessions, participants accomplished the same tasks. During a combined phase of two 120-minute sessions, patients, physicians, and large dialysis organization representatives vetted and developed solutions from earlier phases, leading to an intervention blueprint. Videoconferencing technology allowed for geographically diverse representation and facilitated participation from patients experiencing medical illness. The electronic whiteboard permitted interactive written contributions and voting on priorities instead of only verbal discussion, which may privilege physician participants. A skilled qualitative researcher facilitated the sessions. LIMITATIONS: Challenges included the time commitment of the sessions, absences owing to illness or emergencies, and technical difficulties. CONCLUSIONS: An adapted Design Sprint is a novel method of efficiently and rapidly incorporating multiple stakeholders to develop solutions for clinical challenges in kidney disease. PLAIN LANGUAGE SUMMARY: Stigma contributes to ineffective treatment for pain among individuals with kidney failure on dialysis, particularly when using buprenorphine, an opioid pain medicine with a lower risk of sedation used to treat addiction. To develop a stigma intervention, we adapted a Design Sprint, an industry-developed structured exercise where an interdisciplinary group works over 5 days to clarify the problem, identify and choose a solution, and build and test a prototype. We conducted 3 sprints with (1) patients alone, (2) physicians alone, and (3) combined patients, physicians, and dialysis organization representatives. This paper describes the adaptations and products of sprints as a method for gathering diverse stakeholder voices to create an intervention blueprint efficiently and rapidly.